Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06474182
Recruiting
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Not applicable · France · 1 site
Registry update: 21 Sept 2026
NCT07018050
Recruiting
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 8 Jun 2026
NCT06920251
Recruiting
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Phase 2 · South Korea · 1 site
Registry update: 3 Dec 2025
NCT06487247
Recruiting
HEME Home Transfusion Program
Not applicable · United States · 2 sites
Registry update: 28 Oct 2026
NCT07101705
Recruiting
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Early phase 1 · China · 1 site
Registry update: 21 Jul 2026
NCT06270888
Recruiting
Hypofractionation (Radiation) Trial for Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 30 Mar 2026
NCT06133426
Recruiting
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
Not applicable · France · 1 site
Registry update: 15 Sept 2025
NCT07390071
Recruiting
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Not applicable · United States · 1 site
Registry update: 5 Feb 2026
NCT07025005
Recruiting
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
Phase 4 · Egypt · 2 sites
Registry update: 4 Nov 2025
NCT06933277
Recruiting
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Not applicable · Italy · 1 site
Registry update: 10 Sept 2025
NCT06822972
Recruiting
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Phase 2 · United States · 1 site
Registry update: 3 Sept 2026
NCT06993675
Recruiting
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Phase 2 · United States · 3 sites
Registry update: 6 Nov 2026
NCT07210047
Recruiting
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
Phase 1/2 · Taiwan · 1 site
Registry update: 18 Sept 2026
NCT07106710
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 27 Oct 2026
NCT06832865
Recruiting
ELISA in Relapsed/Refractory MM
Phase 2 · United States · 3 sites
Registry update: 16 Sept 2026
NCT07106736
Recruiting
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 27 Oct 2026
NCT07106671
Recruiting
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 6 Aug 2025
NCT07106684
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Phase 2 · China · 1 site
Registry update: 27 Oct 2026
NCT06974786
Recruiting
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Phase 2 · United States · 11 sites
Registry update: 4 Jun 2026
NCT07105059
Recruiting
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Phase 1 · United States · 7 sites
Registry update: 13 Oct 2026

Ordered by registry start date. Freshness and sponsorship never change the order.